DLA Piper advises on Hong Kong IPO of B&K Corporation

DLA Piper has advised joint sponsors, Huatai Financial Holdings (Hong Kong) and CITIC Securities (Hong Kong), on the Initial Public Offering (IPO) and listing of B&K Corporation on the Main Board of the Hong Kong Stock Exchange (HKEX). The offering raised approximately HK$674 million.

Founded in 2012 and headquartered in Qingdao, China, B&K Corporation Limited is a biopharmaceutical company focused on developing innovative protein-based therapies for wound healing. Its pipeline includes two Core Products, Pro-101-1 for the treatment of thermal burns and Pro-101-2 for diabetic foot ulcers, as well as eight additional candidates. The company focuses on the discovery, development and commercialization of therapies for wound healing, currently platelet-derived growth factor (PDGF) drugs. Proceeds from the IPO are intended to primarily fund the clinical development and commercialization of its products and enhance its R&D capabilities, positioning the company for accelerated growth and market leadership.

The DLA Piper team was led by Hong Kong based corporate partner Christina Loh, with support from Jay Choy (senior associate), Tuo Jiang (registered foreign lawyer), Maisie Yeung (associate), Yu Sun (registered foreign lawyer), Megan Ho (legal assistant), Betsey Shao (paralegal), and Charlotte Wang (legal assistant). Additional support came from partners and teams in Beijing, Singapore, and Shanghai, including Vivian Liu (Head of Capital Markets Compliance, Greater China), Philip Lee (US Securities Partner), as well as Stewart Wang (partner) and Sophia Sun (associate) from Shanghai Kaiman Law Firm, who provided specialized legal advice and support.

Commenting on the listing Christina Loh said: “The successful listing of B&K Corporation Limited highlights the growing investor confidence in innovative biopharmaceutical companies in Hong Kong. This transaction reinforces Hong Kong’s position as a leading market for innovative life sciences companies seeking access to global capital markets.”

Vivian Liu added: “This transaction highlights our capability to coordinate resources efficiently across diverse jurisdictions. Leveraging DLA Piper’s extensive global network, we deliver fully integrated solutions tailored to the complex, cross-border requirements of our clients.”

Stewart Wang commented: “The closing of this transaction reinforces DLA Piper's expertise in bringing biotech companies to list on the Hong Kong Stock Exchange.”